

## Special Issue

# Advances in Cardiovascular Diseases (CVD)

### Message from the Guest Editor

Cardiovascular diseases (CVD) are the most common cause of death worldwide, and despite undeniable progress in prevention and therapeutics protocols, they still remain a relevant clinical issue. This Special Issue will highlight the latest findings in the field of Cardiovascular Diseases involving the pathogenesis and mechanisms of development of CVD, with particular emphasis on endothelial disorders and the potential role of oxidative stress. Studies investigating novel invasive and non-invasive diagnostic tools are also welcomed. The topic of this Special Issue will additionally expand on novel treatment methods in CVD (involving CAD especially high-risk interventions (CHIP), PAD, structural interventions in Heart Diseases, and cardio-renal interventions). Recently, advances in the field of Cardiovascular Diseases have been inextricably linked with the use of bioresorbables; therefore, articles relating to this topic are also highly recommended as a part of this Special Issue. Authors are invited to contribute reviews, original papers. We look forward to receiving your contributions.

### Guest Editor

Dr. Adrian Włodarczak

Department of Cardiology, Miedziowe Centrum Zdrowia, 59-300 Lubin, Poland

### Deadline for manuscript submissions

closed (15 October 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/123379](https://mdpi.com/si/123379)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).